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Abstract
Background: Men with metastatic castrate-resistant prostate cancer can experience an array of treatment-related
side effects. Accumulating evidence suggests exercise may alleviate some of these adversities and assist in disease
management. However, empirical evidence in advanced prostate cancer patients remains limited. The purpose of
this study is to determine whether men with metastatic prostate cancer, who are ineligible for high-intensity
exercise, can partake in a home-based, moderate-intensity exercise program and the impact of doing so on quality
of life and physical fitness parameters.
Methods: Thirty men with adenocarcinoma of the prostate and progressive systemic, metastatic disease will be
recruited. Clinicians will screen patients against inclusion criteria to determine eligibility. All men enrolled will be
prescribed a tailored, home-based, moderate-intensity exercise intervention consisting of aerobic and strengthening
components for 12 weeks. Patients will receive supplementary education materials and weekly behavioural change
consultations throughout the intervention. The primary outcome will be the feasibility of delivering such an
intervention in men with metastatic disease. Secondary endpoints including skeletal events will be monitored for
safety, as will the feasibility of patient-reported outcome measures and the sampling time points, generating data
pertaining to completion rates and potential effect in future trials. General physical fitness will be assessed during
these visits, using timed sit-to-stand testing and a 6-min walking test. Prior to each visit, objective physical activity
levels will be captured for 7 days using an accelerometer, to determine the feasibility of this technology and the
quality of data obtained. In parallel with the feasibility aspects of the trial, changes compared to baseline will be
reported. Direct regular contact will also serve as a feedback loop, should any issues arise. This study has received
ethical approval from the Office for Research Ethics Committees Northern Ireland.
Conclusions: This study aims to determine the potential utility of a home-based exercise intervention in managing
side effects associated with advanced prostate cancer and its treatment. This feasibility trial will inform the design
and implementation of a larger randomised control trial to determine the efficacy of moderate aerobic and
strengthening exercise as an adjuvant therapy in men with metastatic prostate cancer. Collecting such evidence
provides further support for exercise in this paradigm and potential for its inclusion as a low-toxicity therapy in
standard cancer care, in the longer term.
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Introduction
The annual incidence rate for prostate cancer (PCa) in
Northern Ireland is approximately 1100, making it the
most prevalent cancer in males [1]. Of those diagnosed,
20% are advanced cases, characterised by metastatic pro-
gression to secondary sites and the ultimate develop-
ment of resistance to hormone therapy [2]. Some
patients enter the advanced disease state having initially
failed primary treatment with radiotherapy or surgery.
Commonly, metastatic PCa patients receive castration
therapy, usually in the form of luteinising hormone-
releasing hormone agonist (LHRHa) therapy. Despite
significant developments, such methods can cause a
number of adverse effects [3]. Numerous physical prob-
lems are presented (e.g. sexual dysfunction, urinary in-
continence, reduced bone mineral density, increased fat
mass and reduced muscle mass) while psychological is-
sues such as anxiety and depression also arise [4]. Meta-
static spread to the bone is common, subsequently
increasing bone pain and fracture risk and shortening
survival [5, 6]. Men with castrate-resistant, bone meta-
static PCa may also receive chemotherapy, which can
also cause adverse effects including severe fatigue [4].
Thus, the adverse effects of PCa and its treatment
present a considerable clinical issue.
Accumulating evidence suggests that regular exercise
can induce a host of physiological and psychological
benefits, which may alleviate certain treatment-related
toxicities and improve disease outcomes [7, 8]. Previous
exercise research in cancer populations adds further
credibility, to the extent that regular aerobic exercise
may confer a risk reduction of fatality [9]. An initial
study, in men receiving androgen deprivation therapy
(ADT) for localised PCa, reported progressive resistance
training increased muscular strength, endurance and
physical function [10]. A follow-up combined exercise
program reported improved lean muscle mass, muscular
strength, aerobic fitness and quality of life (QOL) while
ameliorating fatigue and inflammation [11]. Other clin-
ical exercise studies also report lower risks in progres-
sion, mortality, cancer-related fatigue and pain [9, 12].
Consequently, tailored exercise has developed into a
promising and effective therapy particularly in localised
PCa [13]. However, the potential mechanism(s) remains
a topic of debate but may be founded in endocrine regu-
lation (insulin-like growth factor (IGF)-1 or testosterone
signalling), metabolism, reactive oxygen species and anti-
oxidant signalling, epigenetics or cytokine signalling
among potential others [14, 15].
Despite early findings, advanced prostate patients are
normally omitted due to their increased risk of fracture
and hence do not avail of such health benefits. Cormie
et al. [16] conducted a preliminary supervised resistance
exercise program in metastatic patients and reported
high retention rates alongside improved physical func-
tion and lean muscle mass compared to the control.
These beneficial changes persisted at 6-month follow-up
along with improvements in QOL [17]. The exercise vol-
ume, including intensity, appears a key mediator in ac-
cruing such health benefits and enhancing survival [9,
18]. This recent progress and international recognition
has resulted in several position stands and expert state-
ments endorsing exercise in cancer care including ad-
vanced cancers [19–23].
Though awareness is increasing, clinical and empirical
evidence in PCa patients with bone metastases remains
limited [16]. Appropriately designed and supervised
training programs have proved feasible and clinically
meaningful, but the chronic effects are yet to be deter-
mined [16]. The Movember GAP4 INTERVAL trial is
seeking to determine such effects through a collabora-
tive, randomised control trial [8]. We anticipate that
some men with advanced disease may be ineligible or
unable to tolerate the exercise component (i.e. high-
intensity training), so we aim to provide a parallel inter-
vention to ensure these men have the opportunity to
capitalise on the benefits of partaking in regular exercise,
albeit at moderate intensity. Our proposed study is the
first to examine the effects of a progressive, home-based,
combined moderate program, with continual behav-
ioural support in this population. Research to date tends
to utilise supervised exercise with good reason and suc-
cess, but at this time an intensive model of exercise is
potentially unsustainable in the UK National Health Ser-
vice (i.e. cost and resource). Home-based exercise is
emerging as a feasible and effective strategy for post-
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therapy cancer survivors [24] and a key component in
future cancer trials [25]. Further, a recent small study of
cancer survivors (n = 20 Australian adults) expressed a
preference for this exercise option [26]; thus, the need to
evaluate a remotely supervised regime in this population
is necessary. This study aims to provide meaningful clin-
ical information with the hope of directly impacting fu-
ture care.
Our primary objective is to establish the feasibility of
delivering an individualised, home-based walking and
strengthening exercise intervention to men with ad-
vanced PCa, who are unable or ineligible for high-
intensity exercise. The feasibility evaluation will address
the accessibility and acceptability of the intervention as
well as recruitment, attrition and exercise adherence
rates. The secondary objectives will (1) determine the
feasibility on QOL, functional ability and patient-
reported assessments and any changes from baseline and
(2) collect preliminary data on health-related QOL and
health resource usage to inform cost-effectiveness. All
men recruited will receive the intervention to refine and
optimise the methodology. Whilst a randomised control
trial (RCT) is the ‘gold standard’ for garnering evidence,
supporting the putative role of exercise in cancer care,
given how resource-intensive and challenging exercise
trials are, we first aim to determine the efficacy and ac-
ceptability in a smaller feasibility study, to determine if
and how the full trial should be conducted [27, 28].
Feasibility trials also improve the chances of conducting
a high-quality RCT and inform methodological design
and resource requirements, to reduce the likelihood of
research waste [28, 29]. We propose this exercise inter-
vention will measurably impact QOL in men with ad-
vanced PCa.
Methods
Study design
This study is a single-arm, feasibility trial coordinated by
Queen’s University Belfast in conjunction with the North-
ern Ireland Cancer Centre (Belfast Health and Social Care
Trust). All patients will be assigned to the exercise inter-
vention to establish feasibility and provide justification for
a randomised control trial. This trial was registered on 5
September 2018 (https://clinicaltrials.gov/ct2/show/
NCT03658486) and has since opened for recruitment. A
chart detailing study procedures can be found in Fig. 1.
This protocol has been developed using the Standard
Protocol Items: Recommendations for Interventional Tri-
als (SPIRIT) guidelines. Figure 2 shows the SPIRIT figure.
Study objectives
The primary objective of this study is to establish the
feasibility of delivering a prescribed exercise intervention
to men with advanced prostate cancer, who are ineligible
for high-intensity exercise (i.e. the Movember GAP4
INTERVAL study). As part of this primary objective, we
will collect data:
 To determine patient eligibility and recruitment
rates.
 To assess adherence to the programme and attrition
rates.
 To determine the rate of exercise-induced adverse
events (if any).
 To ascertain the extent to which the intervention
might be integrated into clinical practice (and the
cost implications of doing so).
 To refine methodological variables, optimising the
study design and data collection processes.
Routine clinic visit for mCRPC patients, as part of standard care.
Screening for eligibility by clinical trials nurses and approved / 
cleared by clinical oncologist. Consultation with patients regarding 
the study specifics / readiness.
Informed consent sought.
Accelerometer fitted and worn for 7 days.
Baseline physical fitness assessment and associated outcome 
measures.  Behavioural change counselling session.
12 week exercise intervention with weekly behavioural support.  7-
day accelerometer data captured during week 12.
Follow-up post-intervention outcome measures alongside an exit 
strategy for continued exercise.
24 week post-intervention outcome measures.  7-day accelerometer 
data captured during week 24.
Qualitative evaluation.
Fig. 1 Study design and patient flow throughout the 24 weeks
and follow-up
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 To explore the perceptions, acceptability and
experiences of men with advanced prostate cancer
undertaking the intervention and those men eligible
that declined participation.
 To explore the perception and experience of those
recruiting to and/or delivering the intervention (e.g.
Exercise Physiologist/Clinical Oncologists/Research
Nurses).
Secondary objectives will focus on the feasibility of
data collection processes, mainly collecting changes in
body composition, functional ability, physical fitness,
physical activity levels and patient-reported outcome
measures (cancer-related fatigue, pain and quality of
life). Additionally, we will use this feasibility trial to col-
lect preliminary data on health resource usage to inform
cost-effectiveness of future trials and refine statistical
considerations (e.g. ascertain sample size estimates).
Progression criteria
Our methods for determining progression to a definitive
RCT are based on recent recommendations [30]. Trial
progression will primarily depend on the feasibility trial
satisfying recruitment targets and secondarily protocol
adherence targets, pre-determined by the trial steering
committee. For example, 75–100% recruitment of the
target sample size will enable progression to a main trial
application, with little or no changes to relevant aspects
of the protocol, while < 25% recruitment will prevent the
trial from progressing. Recruitment of 50–74% will en-
able progression following a review of patients deemed
ineligible or who declined the study invite, recruitment
barriers and possible changes to relevant aspects of the
protocol. Recruitment of 25–49% will only progress if a
‘rescue plan’ can be developed by the trial team and may
involve identifying additional sites or changes to the
protocol. Protocol adherence targets will be held to simi-
lar standards. Objectives relating to the feasibility of data
collection will support the design of a definitive trial, but
we have not assigned progression criteria.
Participants
Men with adenocarcinoma of the prostate and progres-
sive mCRPC will be recruited from the Northern Ireland
Cancer Centre, Belfast. Patients must be on androgen
deprivation therapy (ADT) with a gonadotropin-
releasing hormone (GnRH) agonist/antagonist or have
undergone bilateral orchiectomy. All patients must re-
main castrated throughout the study period. At enrol-
ment, patients must be receiving abiraterone or
enzalutamide, with no evidence of progression. Patients
must also be ≥ 4 weeks since last surgery and fully recov-
ered. At enrolment, patients must have no known con-
traindications to moderate-intensity exercise, including,
STUDY PERIOD
Exercise Trial Close-out
TIMEPOINT Screening Baseline Week 12 Week 24
Qualitative 
evaluation
ENROLMENT:
Eligibility X
Informed consent X
INTERVENTIONS:
Intervention: Exercise
ASSESSMENTS:
Baseline variables X
Follow-up variables X X
Feasibility variables X
Fig. 2 SPIRIT figure
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but not limited to, acute congestive heart failure, un-
stable angina, recent myocardial infarction and periph-
eral neuropathy greater than or equal to grade 3. Men
will be included if they have an Eastern Cooperative On-
cology Group performance status of 0–2. Fluency and
an understanding of English language is also a require-
ment due to the qualitative interviewing component.
Lastly, men will be 18 years of age with no upper age
limit for entry, and medical clearance to partake will be
sought from their treating clinician. Exclusion criteria
can be found in Table 1.
Sample size calculation
As this is a feasibility study, a formal sample size calcula-
tion has not been performed. We aim to recruit 30 pa-
tients to the study which is standard practice for
feasibility trials [31–33]. Assuming an 80% adherence
rate, 25 patients should complete the intervention and
subsequent evaluation.
Screening
The clinical care team will screen clinic lists to deter-
mine eligibility and introduce the study researchers who
can provide further information. While attending treat-
ment clinics, clinical research nurses and members of
the research team will screen each patient against the in-
clusion criteria. Following full disclosure of the study, in-
formed consent will be obtained from each patient.
Participants meeting current physical activity guidelines
(≥ 150 min of moderate-intensity or ≥ 75 min of high-
intensity exercise per week) at screening (determined via
International Physical Activity Questionnaire and in
consultation with an Exercise Physiologist) will be
deemed suitably active and excluded. The remit of this
study is to progressively accrue 150min of moderate-
intensity exercise weekly, so conceivably those already
doing so have a higher exercise tolerance gained through
a process of adaptation and are unlikely to gain the
intended health benefits. Following medical clearance
from a clinical oncologist, patients will be required to
complete a series of baseline questionnaires and will
undertake basic physical fitness and anthropometric
assessments.
Exercise prescription
This multicomponent, self-managed, home-based exercise
strategy has been previously trialled in colorectal cancer
patients (NCT02607787). The program will consist of 12
weeks of moderate-intensity walking (55–70% max HR;
12–14 Borg scale) and strengthening exercises (predomin-
antly body weight; e.g. wall press, sit-to-stand; lateral raise
and bicep curls, using household items for resistance).
Brisk walking was selected as the mode of exercise for this
feasibility trial as it poses a low risk of injury and due to
its popularity, accessibility, cost-effectiveness and ease in
adjusting exercise intensity/demand. Prior to each exercise
session, participants will complete a warm up and at the
end a cool down. Participants will receive a pedometer
and an exercise booklet detailing the desired exercise pre-
scription, allowing space to record daily exertion, particu-
larly the mode, duration and intensity. Information to
enable safe exercise, injury avoidance and overcoming bar-
riers, as well as lifestyle strategies to incorporate exercise,
will also be provided. The exercise program will be indi-
vidually tailored and progressed over the 12-week dur-
ation, aiming to achieve recommended ACSM guidelines
upon completion (Table 2). The individualised, self-
managed nature of the program will allow for a level of
autoregulation allowing modifications based on readiness
and flexibility to complete certain exercises at a later date.
A further advantage of autoregulation is that once patients
become more active, they can work beyond their set pro-
gram (e.g. increase walking distance or intensity). In the
event that metastatic lesions pose a contraindication to
certain exercises, the program will be modified and
adapted. Participants will be required to attend the NICC
to obtain outcome measures (QOL questionnaires, an-
thropometric and physical fitness testing) on three occa-
sions (Table 3). The week prior to each of these visits,
patients will wear an accelerometer to objectively record
7-day physical activity levels (at baseline, 12 and 24 weeks).
Anthropometric measures will comprise height, weight,
hip and waist circumferences while strength and cardio-
vascular endurance will be determined via a timed sit-to-
stand test and 6-min walking test respectively. At 12
weeks, participants, in consultation with the exercise pro-
fessional, will discuss a suitable exit strategy to enable ex-
ercise maintenance. All participants will be followed up at
24 weeks. Though the intervention is predominantly com-
pleted at home, weekly telephone contact permits a degree
of remote supervision. An example of the exercise pre-
scription, for an inactive patient at baseline, can be found
in Table 4.
Behavioural support
The behaviour change component of this particular
programme is based on the COM-B method [34]. Behav-
ioural support will comprise a behavioural change
Table 1 Exclusion criteria
Men currently exceeding ACSM recommended exercise guidelines.
Men with brain metastases.
Men with a currently active second malignancy other than non-
melanoma skin cancer.
Congestive heart failure or recent serious cardiovascular event.
Severe chest pain brought on by exercise.
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consultation at baseline and weekly, structured tele-
phone contact. The behavioural support component will
follow a scripted protocol of defined questioning, to
maintain intervention fidelity. The same member of the
research team will lead the behavioural consultations
throughout, to maintain reliability. Information pertain-
ing to weekly exercise adherence, perceived barriers and
potential solutions, weekly goal setting and self-
confidence will be recorded. Behavioural support ses-
sions provide the opportunity to reinforce key aspects of
the trial and a chance to provide positive feedback on
progress. Records of call durations and patient availabil-
ity will be stored. The behavioural support programme
will ensure continuity in the exercise prescribed, so all
Table 2 Aerobic exercise goals at various time points during the intervention
Week Aerobic exercise targets
3 Walk continuously for 10 min on at least 5 days of the week.
6 Walk continuously for 10 min, twice per day on at least 5 days of the week.
9 Walk continuously for 10 min, three times per day on at least 5 days of the week.
12 Progress to 30 min of brisk walking on at least 5 days of the week.
Table 3 Study assessment schedule
Outcome Screening Baseline Weeks 1–12 Week 12 Week 24 Week 25
Eligibility
Medical history x x x x x
Medication x x x x x
Medical clearance x x x x x
Anthropometric
Height x
Weight x x x
Hip circumference x x x
Waist circumference x x x
Physical fitness
Six-minute walking test x x x
Timed sit-to-stand test x x x
Patient-reported outcomes
FACIT-fatigue x x x
FACT-P x x x
EQ5D x x x
BPI-SF x x x
Self-reported physical activity
IPAQ-short form x x x
Objective physical activity
Accelerometer assessment x x x
Behavioural support
Weekly communication x
Feasibility
Recruitment rates x x
Adherence x x
Attrition rates x x
Safety/adverse events x x
Patient experience x x
Abbreviations: FACIT Functional Assessment of Cancer Therapy, FACT-P Functional Assessment of Cancer Therapy—Prostate, EQ5D EuroQOL five-dimensional
questionnaire, BPI-SF Brief Pain Inventory—Short Form, IPAQ International Physical Activity Questionnaire
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patients receive equal support to meet the desired exer-
cise volume by study cessation. The purpose of this
communication is to maintain a close relationship with
the patient and identify additional support required. Ac-
curate recording of physical activity data is essential to
enable associations with treatment-related adversities
and the outcome markers. Participants will specify their
preferred communication type (if not telephone), to en-
sure regular contact is maintained.
Primary endpoint
The primary endpoint is to determine the feasibility of
delivering a tailored, home-based, 12-week exercise
intervention in men with metastatic castrate-resistant
prostate cancer. Recruitment and attrition rates, exercise
adherence (number of sessions completed), general
safety/adverse events and the patient experience will be
a focus of determining feasibility.
Secondary endpoints
Secondary endpoints will be assessed at baseline, 12 and
24 weeks accounting for pain, cancer-related fatigue,
skeletal-related events, physical fitness and QOL. Direct
contact throughout the study will also serve as a feed-
back loop for certain measures should they occur out-
side each visit. Secondary outcome measures will be
assessed mainly for completeness in accordance with the
feasibility theme of the study. Although the sample size
is small and perhaps underpowered to definitely report
causation, changes from baseline will be analysed, to
provide an indication of efficacy and detect any differ-
ences. It should be noted that all secondary outcome
measures are obtained principally for testing the ability
to undertake and complete measures and not to detect
differences from baseline. Processes relating to data
handling and analysis are described in greater detail in
the “Data analysis” section.
Pain progression and opiate use
Pain and analgesic management using opiates will be
assessed using the Brief Pain Inventory Short Form
(BPI-SF) [35] and a review of medical records at base-
line, 12 and 24 weeks. The BPI was originally developed
to assess pain severity and impact in cancer patients, with
reported good internal consistency and validity [36, 37].
The BPI-SF is now widely recommended as a core out-
come measure in clinical trials.
Skeletal-related events
Symptomatic skeletal-related events (SSEs) will be
determined at treatment clinics and reviewing patient
medical records, continuously throughout the 24-week
intervention.
Table 4 Weekly exercise prescription example
Week Exercise prescription
1 AE: MIW for 10 min; once per day; at least 2 days of the week.
STE: One set of 8–15 repetitions (2 exercises); on 2–3 days of the week.
2 AE: MIW for 10 min; once per day; at least 3 days of the week.
STE: Two sets of 8–15 repetitions (2 exercises); on 2–3 days of the week.
3 AE: MIW for 10 min; once per day; at least 5 days of the week.
STE: Three sets of 8–15 repetitions (2 exercises); on 2–3 days of the week.
4 AE: MIW for 10 min; once per day; at least 5 days per week (additional goal: on 2 or more days add another 1 × 10 min bout).
STE: Same as week 3; add 1 set of 2 new exercises (4 total); 8–15 repetitions on 2–3 days.
5 AE: MIW for 10 min; once per day; at least 5 days of the week (additional goal: on 2 or more days add another 1 × 10 min
bout).
STE: Same as week 3; add 2 sets of 2 new exercises (4 total); 8–15 repetitions on 2–3 days.
6 AE: MIW for 10 min; twice per day; at least 5 days of the week (additional goal: on 2 or more days add another 1 × 10min
bout).
STE: Same as week 3; add 3 sets of 2 new exercises (4 total); 8–15 repetitions on 2–3 days.
7 AE: MIW for 10 min; twice per day; at least 5 days of the week (additional goal: on 2 or more days add another 1 × 10min
bout).
STE: Same as week 6; add 1 set of 2 new exercises (6 total); 8–15 repetitions on 2–3 days.
8 AE: MIW for 10 min; twice per day; at least 5 days of the week (additional goal: on 3 or more days add another 1 × 10min
bout).
STE: Same as week 6; add 2 sets of 2 new exercises (6 total); 8–15 repetitions on 2–3 days.
9 AE: MIW for 10 min; twice per day; at least 5 days of the week (additional goal: on 3 or more days add another 1 × 10min
bout).
STE: Same as week 6; add 3 sets of 2 new exercises (6 total); 8–15 repetitions on 2–3 days.
10–12
(maintenance)
AE: MIW for 30 min on at least 5 days of the week.
STE: Same as week 9. For continued progression, add another set of each exercise.
Abbreviations: AE aerobic exercise, MIW moderate-intensity walking, STE strength training exercise
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Fatigue and QOL measures
Cancer-related fatigue will be determined using the
FACIT fatigue scale at baseline, 12 and 24 weeks [38].
The Functional Assessment of Cancer Therapy—Pros-
tate (FACT-P) and EuroQOL five-dimensional question-
naire (EQ-5D-5 L) will be measured at the same time
points to assess QOL. Both questionnaires are inter-
nationally recognised validated measures for all stages of
prostate cancer and are sensitive to changes in indicators
of treatment efficacy [39–41]. The change in score for
the FACT-P and FACIT fatigue questionnaires can be
calculated for each participant and categorised according
to pre-established minimally important differences
(MIDs). The EQ-5D-5 L will be used as a general index
of health status and to inform the cost-effectiveness of
future trials across the five dimensions.
Physical activity levels
Each patient’s level of physical activity will be assessed
subjectively at baseline, 12 and 24 weeks using the Inter-
national Physical Activity Questionnaire Short Form
(IPAQ-SF). Craig et al. [42] reported the IPAQ-SF pro-
duced repeatable data and has acceptable measurement
properties for self-report physical activity. Lee and col-
leagues [43] have reported the IPAQ-SF typically overes-
timates physical activity and thus should be
supplemented with objective measures. In order to pre-
vent this potential overestimation, this questionnaire will
be completed in consultation with an Exercise Physiolo-
gist. Further, to complement the subjective assessment,
objective physical activity will be captured the week
prior to each outcome visit, using an accelerometer
(ActiGraph GT3X). The accelerometer will be worn for
7 days, capturing data at 10-s Epoch intervals. The ana-
lysis will be completed at 60-s Epoch intervals, in ac-
cordance with recommendations [44, 45]. Moderate to
vigorous physical activity and step counts will be
assessed for each patient.
Physical fitness
Physical fitness will be assessed at baseline, 12 and 24
weeks using a timed sit-to-stand test (30 s) and 6-min
walking test. The number of repetitions will be recorded
during the sit-to-stand test, while the distance covered
will determine aerobic fitness.
Qualitative evaluation
Upon study completion (week 24), the impact and expe-
riences of key stakeholders including active participants,
eligible patients that declined participation and the re-
search staff delivering the intervention will be collected,
via face-to-face semi-structured interview. Men who de-
clined to participate will be given the opportunity to dis-
cuss their decision and gather information on suitable
alternatives. Study staff interviews will be conducted by
an impartial colleague to reduce bias.
The feasibility, acceptability, potential utility of the
program, approaches to optimise and appropriateness of
the timing and outcome measures will be a priority dur-
ing interviewing. The semi-structured interviews will ex-
plore perceived facilitators and barriers to exercise and
experiences of exercise in managing treatment-related
symptoms, with common themes extracted during con-
tent analysis. Information relating to the number
screened and eligible, retention and compliance, follow-
up rates and satisfaction will be recorded on a discussed
weekly but revisited during interviewing, followed by a
descriptive analysis. Interviews will be tape-recorded and
transcribed verbatim.
Ethical approval
Ethical approval to conduct this study was obtained
from the Office for Research Ethics Committees North-
ern Ireland (ORECNI) in 2018 (IRAS project ID:
248301). Any subsequent protocol modifications will be
reviewed by ORECNI. Following approval, a memoran-
dum, detailing the amendment, will be issued to all
members of the trial steering committee.
Data management and monitoring
All data collected will be stored securely in accordance
with General Data Protection Regulations (within a key
card accessed building, on a password-protected com-
puter and locked filing cabinet). Only members of the
study management team will have access to this data. A
trial steering committee (comprising MB, MM, LM,
HM, JMO, SJ, GP and NICRCF advisory group mem-
bers) will oversee the trial and convene regularly to dis-
cuss pertinent aspects of the study. As clinical
oncologists sit on this trial steering committee, we felt a
trial data monitoring committee was not required. Spon-
taneous adverse events will be captured during regular,
weekly contact with patients. Any adverse events will be
expedited to the trial oncologists, upon report, for an
immediate resolution and further reviewed at regular
committee meetings. This trial will be subject to audit
from the study sponsor, who has the power to terminate
the trial if necessary. Trial results will be submitted for
publication and communicated in a relevant medical or
scientific journal. Anonymity will be maintained and
unique identifiers will be removed in any subsequent
outputs.
Data analysis
From a feasibility perspective, data analysis will account
for the number of patients screened, numbers participat-
ing in the intervention and the numbers unwilling to
participate, after eligibility is confirmed, with reasons for
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non-participation. This data will be examined and scruti-
nised using descriptive analysis to identify differences
between participants and non-participants. Patient com-
pliance, utilisation and satisfaction with the intervention
will be assessed, as will completion rates for the inter-
vention and the outcome measures. The acceptability of
the physical outcome measures and questionnaires used
in determining health resource use will also be reported.
Additionally, the feasibility of the accelerometer data
(e.g. volume and quality) will be analysed. All measures
will be scored according to standard practice and ana-
lysed for mean changes from baseline, using a one-way
repeated measures ANOVA. For each outcome measure,
change will be calculated as follow-up (at both 12 and
24 weeks) minus baseline and presented alongside 95%
CIs. We will also calculate effect size (Cohen’s d) for
each outcome measure, at 12 and 24 weeks, using the
following formula: (mean post-test − mean baseline)/
(baseline standard deviation). Conventions of small (d =
0.20), medium (d = 0.50) and large (d = 0.80) will be
used. Preliminary feasibility results will inform the fu-
ture RCT sample size calculation and the parameters
for investigation to determine potential clinical
meaningfulness.
Transcriptions of audio recorded interviews will be
analysed using thematic analysis [46]. At each stage,
findings will be verified and discussed in order to assess
the accuracy of the interpretation, promote reliability
and ensure rigour [47]. NVivo qualitative data analysis
software will be used to aid data management. Data gen-
erated from interviewing will assist in determining the
safety of the intervention as well as the health economics
moving forward.
Discussion
Accumulating evidence supports the putative synergistic
role of exercise in managing the myriad of treatment-
related adversities associated with prostate cancer [2].
Data from recent epidemiological studies provides fur-
ther recognition of the association between exercise and
a reduced risk of prostate cancer mortality [18, 48, 49].
Collectively, we now have level 1 evidence that exercise
is effective in improving QOL, fatigue and exercise toler-
ance in men with prostate cancer, with higher quality re-
sults observed in advanced cases treated with ADT [7].
Commonly, due to the high-risk nature of advanced
prostate cancer (i.e. heightened risk of fractures) as well
as poor retention and compliance, supervised exercise is
advocated and has proved effective. Yet, despite the re-
ported benefits such a regime, at this time, is economic-
ally unsustainable in current NHS settings, due to the
limited number of specialist exercise professionals,
equipment and resources, highlighting a necessity for es-
tablishing an alternative. Culos-Reed and colleagues [50]
successfully implemented a tailored, partly home-based
intervention and reported an attenuation of the side ef-
fects associated with treatment. Recently, Hardcastle et
al. [26] presented several key variables that influence ex-
ercise participation in cancer populations including
availability, access, time, cost and confidence. A notable
finding identified a keen interest in home-based, re-
motely supervised exercise alongside professional exer-
cise counselling [26].
Implementing a remotely supervised walking and
strengthening programme with sufficient, ongoing be-
havioural support is appealing and can overcome many
perceived barriers, in terms of its practicality (incorpor-
ating into daily living) and cost-effectiveness (home-
based with little investment in equipment or member-
ships). We hope this intervention caters for perceived
patient preferences and will assist in uptake and adher-
ence, but admittedly may prove resource intensive, with
dedicated researcher time invested in weekly contact.
Perhaps exercise provision for mCRPC patients could
eventually be embedded in the standard of care follow-
up consultations between patients and trained, specialist
nurses/physiotherapists, if feasible, to alleviate some of
this time burden, while resulting in a coordinated effort
to facilitate behavioural change. This study will investi-
gate whether men with advanced prostate cancer can
take part in a home-based, progressive, moderate-
intensity exercise program and its effect on treatment-
related side effects. We propose that providing the ne-
cessary education and continual behavioural support will
empower patients and enhance their self-efficacy, a key
variable in maintenance. The potential utility of home-
based exercise in assisting disease management is of
clinical interest and warrants further scientific investiga-
tion, highlighting a rationale for the current study.
Trial status
This feasibility trial commenced recruitment in Decem-
ber 2018 and is currently ongoing. At the time of sub-
mission of this protocol, seven patients have consented
and entered the trial.
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